Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A new program aims to ease the 'Lost in Transition' struggle for cancer survivors

NCT ID NCT05534386

Disease control Sponsor: The University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial tests a survivorship care program for Chinese cancer survivors who have recently finished curative treatment. The program includes a one-off assessment and personalized advice, with an optional step-up intervention focusing on symptom management and weight control. Researchers will see if it reduces physical symptom distress, improves weight management, and boosts quality of life compared to standard pamphlets.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A self-management based survivorship care program, including a one-off face-to-face assessment and personalized advice, with optional step-up targeted intervention focusing on symptom management and weight control.
What this could lead to
If successful, this program could offer a practical way to help cancer survivors manage lingering symptoms and weight issues after treatment, improving their quality of life.
What could go wrong
This is an early-stage trial, and the program's benefits are not guaranteed. It may not work for everyone, and the personalized step-up approach adds complexity that could affect results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 486 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Cantonese- or Mandarin-speaking Chinese patients diagnosed curable cancer * have completed primary and adjuvant treatment within the past six months Exclusion Criteria: * Patients diagnosed with metastatic cancer

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neoplasms Physical symptom distress Weight management

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Kwong Wah Hospital-Breast Center

    ACTIVE_NOT_RECRUITING

    Hong Kong, Hong Kong

  • Pamela Youde Nethersole Eastern Hospital-Department of oncology

    ACTIVE_NOT_RECRUITING

    Hong Kong, Hong Kong

  • Prince of Wales Hospital-Department of Surgery

    ACTIVE_NOT_RECRUITING

    Hong Kong, Hong Kong

  • Queen Mary Hospital-Department of Obstetrics & Gynaecology

    RECRUITING

    Hong Kong, Hong Kong

  • Queen Mary Hospital-Department of Oncology

    RECRUITING

    Hong Kong, Hong Kong

  • Queen Mary Hospital-Department of Surgery

    RECRUITING

    Hong Kong, Hong Kong

  • Tung Wah Hospital-Department of Surgery

    ACTIVE_NOT_RECRUITING

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.